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Abstract The von Hippel^Lindau (VHL) tumor suppressor
gene regulates the extracellular matrix by controlling ¢bronec-
tin deposition. To identify novel VHL target genes, we subjected
mRNA from VHL-de¢cient RCC cells (786-0-pRC) and a
transfectant re-expressing wildtype VHL (786-0-VHL) to di¡er-
ential expression pro¢ling. Among the di¡erentially expressed
genes, we detected that ¢bronectin is upregulated in the presence
of VHL, while it is not a¡ected by hypoxia. Thus regulation of
¢bronectin deposition by VHL occurs at the transcriptional lev-
el, irrespective of oxygen levels.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Von Hippel^Lindau disease is caused by inactivation of the
von Hippel^Lindau (VHL) tumor suppressor gene, and is
characterized by the formation of hypervascularized neo-
plasms, including virtually all sporadic and inherited renal
cell carcinomas (RCCs) [1,2]. VHL functions as the substrate
recognition moiety of the E3 ubiquitin ligase complex VCB^
CUL2 E3, which targets the K-subunit of the hypoxia-induc-
ible factor (HIF) for degradation by the proteasome under
normoxic conditions [3]. HIF is a transcription factor regulat-
ing genes encoding proteins that function to increase O2 de-
livery, allow metabolic adaptation and promote cell survival
[4]. RCCs lacking functional VHL exhibit high levels of sta-
bilized nuclear HIF, resulting in excessive transcription of
HIF target genes, the best documented of which being the
vascular endothelial growth factor (VEGF) [5,6]. HIF-inde-
pendent functions of VHL have been described in recent liter-
ature. VHL binds the extracellular matrix (ECM) protein ¢-
bronectin; VHL-de¢cient cells show impaired ¢bronectin de-
position possibly contributing to tumorigenesis and directly
in£uencing the behavior of tumor cells [7].
We and others have previously demonstrated that VHL
appears to control ECM degradation by regulating both met-
alloproteinases-2 and -9 and their inhibitors [8], as well as the
urokinase-type plasminogen activator system [9,10]. In addi-
tion, by promoting the assembly of actin and vinculin, VHL
was found to a¡ect cytoskeletal organization, focal adhesion
formation and cell motility [11]. VHL in£uences e¡ects on
proliferation, cell cycle progression, as well as alterations of
the ECM interactions. Furthermore, ¢bronectin gene (FN1)
expression has been correlated with increased tumor cell
growth and invasiveness of VHL-defective RCCs [12].
To identify novel VHL target genes, we subjected a VHL-
de¢cient RCC cell line (786-0-pRC) and transfectants re-ex-
pressing wildtype VHL cDNA (786-0-VHL) to di¡erential ex-
pression pro¢ling and identi¢ed a group of 16 genes that were
either negatively or positively regulated by VHL. Of these
genes two interesting features were noticed. The ¢rst was a
group of genes positively regulated by VHL. Our results con-
¢rmed and expanded earlier reports using di¡erential hybrid-
ization [11,13^16]. Interestingly, we identi¢ed the gene encod-
ing ¢bronectin, FN1, as a gene positively regulated by VHL,
though its transcription levels are unaltered by hypoxia. These
data support the hypothesis that VHL also regulates tran-
scription in a HIF-independent manner. Secondly, our data
suggest that VHL regulates ¢bronectin mRNA levels. This
knowledge, taken together with the fact that VHL binds ¢-
bronectin, increases our understanding of how VHL regulates
¢bronectin deposition.
2. Materials and methods
2.1. Cell lines
Stable transfectants of 786-0 cells expressing vector backbone alone
(786-0-RC) or wildtype VHL (786-0-VHL) (obtained from W. Kaelin,
Dana Farber Cancer Institute, USA) were grown in Dulbecco’s modi-
¢ed Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal calf serum (Invitrogen), L-glutamine (2 WM), penicillin
(50 IU/ml), and streptomycin sulfate (50 Wg/ml) (Invitrogen).
2.2. RNA isolation
Total RNA was isolated using RNAzol B as described by the man-
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ufacturer (Campro Scienti¢c, Veenendaal, The Netherlands) and dis-
solved in DepC-treated Milli-Q H2O. Poly(A)þ RNA was extracted
and puri¢ed using the Oligotex mRNA Mini kit (Qiagen, Valencia,
CA, USA).
2.3. Microarray analysis
Poly(A)þ RNA (1 Wg) of each sample was reverse transcribed into
cDNA using a reverse transcription kit (Invitrogen) in combination
with an oligo-dT15 primer (Invitrogen) and amino allyl containing
dUTPs (Sigma, St. Louis, MO, USA). cDNAs were £uorescently la-
beled with either Cy3 or Cy5 (Amersham Biotech, Buckinghamshire,
UK). Chroma-spin columns were used to remove unincorporated Cy
dyes (Clontech, Palo Alto, CA, USA). Labeled cDNAs (100 ng per
sample in hybridization bu¡er) were subjected to competitive hybrid-
ization on a 1.7 K human microarray (obtained from the Microarray
Facility of University of Toronto; http://www.uhnres.utoronto.ca/
services/microarray). Hybridization bu¡er contained 25% formamide,
2.5Usodium saline citrate (SSC), 0.2% sodium dodecyl sulfate (SDS),
100 Wg/ml herring sperm DNA and 200 Wg/ml Escherichia coli tRNA.
A coverslip (25U25 mm) was applied to the microarray after which 30
Wl of hybridization mix was applied to hybridize in a hybridization
chamber (Corning, New York, NY, USA) overnight in a 42‡C water
bath. After hybridization, microarrays were washed at room temper-
ature in 1USSC with 0.2% SDS for 4 min, 0.1USSC with 0.2% SDS
for 4 min, and 0.1USSC for 4 min, successively. Subsequently, micro-
arrays were dried by centrifugation (5 min at 124Ug) and scanned
using a confocal laser scanner (Packard Scanarray 4000XL from Per-
kin Elmer, Boston, MA, USA). Data were analyzed using Imagene
software (Biodiscovery, El Segundo, CA, USA).
2.4. RT-PCR analysis
Total RNA (1.5 Wg) was reverse transcribed to obtain cDNA for
reverse transcription polymerase chain reaction (RT-PCR) using
SuperScript II RNase H3 Reverse Transcriptase (according to the
manufacturer, Invitrogen). Gene-speci¢c cDNA fragments were am-
pli¢ed by 25 cycles of PCR consisting of 1 min at 95‡C, 1 min at 55‡C
and 2 min at 72‡C. PCR fragments were analyzed by DNA gel elec-
trophoresis. The following primers were used for RT-PCR: VEGF
forward primer: 5P-cgaaaccatgaactttctctgc, reverse primer: 5P-ccact-
tcgtgatgattctgc, glucose transporter-1 (GLUT-1) forward primer: 5P-
ttcaatgctgatgatgaacc, reverse primer: 5P-gtacacaccgatgatgaagc, insulin-
like growth factor binding protein-3 (IGFBP3) forward primer: 5P-
gaacttctcctccgagtcc, reverse primer: 5P-ccttcttgtcacagttggga, FN1 for-
ward primer: 5P-caagccagatgtcagaagc, reverse primer: 5P-ggatggtgcat-
caatggca, 18S forward primer: 5P-agttggtggagcgatttgtc, reverse prim-
er: 5P-tattgctcaatctcgggtgg.
2.5. Western analysis
Approximately 1U106 cells were lysed in 400 Wl lysis bu¡er (20 mM
Tris^HCl pH 8.0; 1% Triton X-100; 140 mM NaCl; 10% glycerol;
0.005% bromophenol blue; 8% L-mercaptoethanol) containing the
‘complete’ cocktail of protease inhibitors (Roche, Basel, Switzerland).
Cell remnants were removed by centrifugation (5 min at 16 100Ug at
4‡C) and cleared lysates were stored at 320‡C. Approximately 20 Wg
of protein per lane was analyzed by SDS^polyacrylamide gel electro-
phoresis followed by Western blotting using a polyclonal antibody
speci¢c for IGFBP3 (1:200; kind gift from Dr. J. van Doorn, WKZ
Utrecht, The Netherlands), and monoclonal antibodies for ¢bronectin
(1:500; M010, FN30-8, TaKaRa Biomedicals, Shiga, Japan) and for
VHL (1:500; IG32, BD-Pharmingen, San Diego, CA, USA), respec-
tively. Antibodies were diluted in phosphate-bu¡ered saline contain-
ing 5% non-fat dried milk and 0.1% Tween 20. Swine anti-rabbit or
rabbit anti-mouse horseradish peroxidase (1:10 000; Pierce, Rockford,
IL, USA) was used as a secondary antibody and enhanced chemilu-
minescence (Perkin Elmer) was used for detection.
2.6. IGFBP3 and ¢bronectin detection assays
Secretion levels of IGFBP3 in conditioned medium were determined
as described previously [17]. Secretion levels of ¢bronectin were de-
termined by sandwich enzyme-linked immunosorbent assay (ELISA)
[18] using a polyclonal antibody speci¢c for ¢bronectin and a mono-
clonal antibody against ¢bronectin (respectively M010 and FN30-8,
TaKaRa Biomedicals). Rabbit anti-mouse peroxidase was used as a
third antibody for detection and quanti¢cation.
2.7. Real-time PCR
Real-time PCR was performed using the iCycler iQ real-time PCR
detection system (Bio-Rad, Hercules, CA, USA). An optical 96 well
reaction plate (Bioplastics, North Ridgeville, OH, USA) and iCycler
iQ sealing tape (Bio-Rad) were used for PCR ampli¢cation. The ¢nal
reaction mixture of 15 Wl consisted of diluted cDNA, 1UPCR bu¡er
(Amersham Biotech), 0.05 mM dNTPs (Amersham Biotech), 100 WM
forward primer, 100 WM reverse primer and 0.375 U Taq polymerase
(Amersham Biotech). For detection of the PCR product in real time,
the SYBR green I £uorophore (Roche) was used in a ¢nal 10 000-fold
dilution. The cDNA was further diluted six-fold or 2000-fold prior to
PCR ampli¢cation of GLUT-1, IGFBP3 and FN1 or 18S, respectively.
Gene-speci¢c cDNA fragments, using the same primers as mentioned
before, were ampli¢ed by 40 cycles of PCR consisting of 30 s at 94‡C,
30 s at 58‡C and 30 s at 72‡C. For each assay, speci¢c targets were
ampli¢ed in triplicate with their respective standard curves. The equa-
tion of the standard curve was used to determine the starting quantity
of the samples with the iCycler analysis software. All experimental
samples were normalized to 18S quantities.
Table 1
VHL target genes
Accession number Gene ID Cy3/Cy5 log2 ratio Biological function
Upregulated
AA099195 GDIB (GDP dissociation inhibitor B) 1.2 Intracellular vesicle transport
AA136799 GADD45 (Gene activated by DNA damage) 0.7 Stress response; cell cycle arrest; cell
death
AA195589 FN1 (Fibronectin) 1.6 Cellular adhesion
H07071 VCAM1 (Vascular cell adhesion molecule 1) 0.8 Cellular adhesion
R81846 FRIL (Ferritin light chain) 0.8 Metal transport; RNA stability
W69515 MKK2 (Mitogen-activated protein kinase kinase 2) 0.8 Stress response; nuclear export; cell
growth
H52752 GR75 (Heat shock 70 kDa protein) 0.7 Stress response; cell growth; cellular
aging
AA023029 PPP5 (Serine/threonine protein phosphatase 5) 0.7 Mitosis; RNA biogenesis, transcription
AA151568 TEGT (Testis enhanced gene transcript) 0.7 Cell death
H02641 VHL (Von Hippel^Lindau) 0.9
Downregulated
AA037034 COXA (Cytochrome c oxidase 31.0 Metabolic response; electron transfer
H86642 CERU (Ceruloplasmin) 31.0 Metabolic response; copper transport
N31417 IGFBP3 (Insulin-like growth factor binding protein 3) 32.3 Cell growth
N40420 CGD1 (Cyclin D1) 30.8 Cell growth; cell cycle regulator
N91060 VEGF (Vascular endothelial growth factor) 30.9 Angiogenesis ; cell growth
N31209 NUP153 (Nucleoporin 153) 30.8 Nuclear-cytoplasmic transport
R92231 TLE1 (Transducin-like enhancer protein 1) 30.7 Cell di¡erentiation; cell fate
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3. Results and discussion
3.1. Identi¢cation of VHL-regulated genes by microarray
analysis
In an attempt to identify novel VHL target genes involved
in tumorigenesis, we subjected mRNA from a VHL-defective
renal carcinoma cell line (786-0-pRC) and transfectants re-
expressing a wildtype VHL allele (786-0-VHL) to di¡erential
expression pro¢ling. A glass chip-based cDNA array repre-
senting about 1700 distinct human genes was spotted in du-
plicate (obtained from the Microarray Facility of the Uni-
versity of Toronto: http://www.uhnres.utoronto.ca/services/
microarray). The cDNA made from puri¢ed mRNA from
786-0-VHL cells was labeled with Cy3 and mixed with Cy5-
labeled cDNA transcribed from 786-0-pRC puri¢ed mRNA.
After normalization, the Cy3/Cy5 ratio of each gene individ-
ually was determined from three independent experiments and
overlapping sets of genes were selected. In this way nine genes,
with an average log2 ratio above 0.7, were considered posi-
tively regulated by VHL, whereas seven genes that had an
average log2 ratio of 30.7 or below, were considered nega-
tively regulated (Table 1). The expression of the GAPDH gene
was not regulated by VHL (not shown). In addition, the aver-
age Cy3/Cy5 log2 ratio of the VHL gene (as expected above
0.7) was used as an internal control as a measure of the reli-
ability of the observed changes.
RT-PCR was performed as an independent test to con¢rm
the di¡erential expression of some of the genes identi¢ed by
DNA microarray. As shown in Fig. 1, the expression of FN1
and VHL was shown to be higher in 786-0-VHL cells than in
786-0-pRC cells. The opposite was true for CERU, IGFBP3
and VEGF. The expression of GAPDH was taken as an in-
ternal control. In conclusion, similar expression patterns of
VHL target genes were found when measured by these two
independent methods.
Using the Gene Ontology Consortium classi¢cation of bio-
logical processes, these target genes could be classi¢ed accord-
ing to their biological function (Table 1). In this way, VHL
was shown to be a negative regulator of genes involved in cell
proliferation such as IGFBP3 and CGD1. Moreover, VHL
appeared to positively regulate GADD45, a gene involved in
cell cycle arrest, as well as FN1 and VCAM1 (encoding the
vascular cell adhesion molecule), both of which have roles in
cell adhesion. Literature searches revealed that eight of the
VHL target genes identi¢ed in our study (VEGF, CERU,
COXA, IGFBP3, CGD1, GADD45, VCAM1, and FN1) have
been previously implicated in the development of RCC [19^
23]. We further focused on ¢bronectin as this protein is re-
ported to interact with VHL and is believed to be regulated in
a post-transcriptional manner by VHL. However, the tran-
Fig. 1. FN1 gene expression is positively regulated by VHL. Gene
expression levels of CERU, IGFBP3, FN1, VEGF, VHL, and
GAPDH were determined by RT-PCR analyses. All panels show
speci¢c products for the indicated genes. Left lanes represent VHL
mutant cell line 786-0-RC (RC); right lanes represent the same cell
line stably overexpressing VHL, 786-0-VHL (VHL). The housekeep-
ing gene GAPDH functions as a control for loading. Previously re-
ported in the literature, VEGF, CERU, and IGFBP3 are all nega-
tively regulated by VHL. FN1 expression, however, is regulated by
VHL in the opposite manner.
Fig. 2. Quanti¢cation of IGFBP3 and FN1 gene expression. A: Lev-
els of ¢bronectin mRNA expression were determined by real-time
PCR. The amount of mRNA measured in the 786-0-VHL cell line
(VHL) was normalized to 1 and the amount of mRNA in the 786-
0-RC cell line (RC) is relative to this amount. Each individual point
in the plot is an independent measurement. There is a statistically
signi¢cant upregulation of ¢bronectin in the presence of VHL.
B: Quanti¢cation of IGFBP3 mRNA expression performed as de-
scribed above shows a statistically signi¢cant decrease of mRNA
levels in the presence of VHL.
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scriptional regulation of FN1 by VHL has not been previously
reported.
3.2. Role of VHL in regulation of ¢bronectin
Levels of ¢bronectin mRNA increased 3.7-fold in the pres-
ence of VHL as measured by repeated real-time PCR analyses
(Fig. 2), IGFBP3 was used to study the behavior of genes
downregulated by VHL. Protein expression levels were deter-
mined in whole cell lysates of 786-0-VHL versus 786-0-pRC
cells by Western analysis. Fig. 3A correlates higher ¢bronectin
levels with VHL in 786-0-VHL cells. In contrast, increased
levels of IGFBP3 were detected in 786-0-pRC cells as com-
pared to 786-0-VHL cells. Conditioned medium of 786-0-pRC
and 786-0-VHL cells recapitulated the di¡erential secretion of
¢bronectin and IGFBP3 (Fig. 3B). 786-0-VHL cells secreted
15-fold more ¢bronectin than 786-0-pRC cells. Accordingly,
IGFBP3 secretion was relatively high (20-fold) in cultured
medium from 786-0-pRC cells when compared to that of
786-0-VHL cells. Together, these data imply that aberrant
production and secretion of ¢bronectin and IGFBP3 is di-
rectly related to VHL expression in RCC cell lines. It is worth
noting that ¢bronectin mRNA levels are remarkably less sen-
sitive to re-expression of VHL than detectable secreted protein
levels (approximately four-fold, discussion below).
Fibronectin is an extracellular glycoprotein that binds to
and signals through heterodimeric cell surface receptors
known as integrins [24]. Loss of ¢bronectin matrix assembly
has been recognized as a feature of cellular transformation
[25]. Fibronectin has the ability to decrease the metastatic
behavior of malignant cells by increasing the interaction be-
tween tumor cells and their microenvironment via the integrin
receptor family [26]. Furthermore, ¢bronectin can revert some
aspects of the malignant phenotype of tumor cells, including
proliferation and migration [27]. Previous reports have de-
scribed a physical interaction between VHL and intracellular
¢bronectin in vivo; this interaction a¡ected the ability of cells
to assemble an extracellular ¢bronectin matrix [7]. We report
here ^ using the same cell system used to determine VHL^
¢bronectin binding ^ that ¢bronectin mRNA levels are regu-
lated by VHL. The di¡erence in ¢bronectin secretion in our
experiments could not be directly accounted for by mRNA
increase (15-fold vs. 3.7-fold). Our data thus do not exclude
the notion that VHL binding to ¢bronectin regulates the
amount of ¢bronectin deposition in a post-transcriptional
manner [7]. However, we propose an additional way that
VHL regulates ¢bronectin: at the transcriptional level.
3.3. E¡ect of hypoxia on the VHL target genes FN1 and
IGFBP3
Because many of the known VHL target genes (including
VEGF) are regulated by the HIF transcription factors, we
next determined the e¡ect of hypoxia on the expression of
FN1 and IGFBP3. Therefore, we cultured 786-0-VHL or
786-0-pRC cells under normoxic (20% O2) or hypoxic (1%
O2) conditions for 18 h. Total RNA was extracted from these
cells and subjected to quantitative real-time PCR to follow the
expression of GLUT-1 (which is a known hypoxia-inducible
gene) [4], IGFBP3 and FN1. The expression of 18S (which is
not a¡ected by hypoxia) was taken as an internal control and
used to normalize expression of GLUT-1, IGFBP3 and FN1.
As shown in Fig. 4A, hypoxia signi¢cantly induces the ex-
pression of GLUT-1 by 6.7-fold in 786-0-VHL cells after 18 h
of hypoxic treatment (P=0.025; Fig. 4A). In 786-0-pRC cells
the expression of GLUT-1 mRNA was not signi¢cantly
changed. Similar results were also shown for VEGF expression
under these conditions (data not shown). As expected, hypox-
ia also induced IGFBP3 mRNA expression (approximately
¢ve-fold; P=0.029) in 786-0-VHL cells, whereas in the ab-
sence of functional VHL (i.e. 786-0-pRC), IGFBP3 expression
did not di¡er signi¢cantly (Fig. 4B). This implied a role of
HIF in the regulation of the IGFBP3 gene by VHL. Although
the expression of both GLUT-1 and IGFBP3 in 786-0-pRC
was not signi¢cantly altered by hypoxia, a trend towards in-
duction of transcription was present (Fig. 4A,B). In contrast,
Fig. 3. Secretion of IGFBP3 and ¢bronectin is inversely regulated by VHL. A: Intracellular protein levels of IGFBP3, ¢bronectin and VHL de-
termined by Western blot analyses. Left and right lanes contain protein lysates derived from 786-0-RC cell line (RC) and 786-0-VHL (VHL)
cell lines, respectively. Upper panel: ¢bronectin levels increase in the presence of VHL. Middle panel: less IGFBP3 is detected in the presence
of VHL. Lower panel: VHL levels. B: Levels of secreted IGFBP3 and ¢bronectin (FN) depicted left and right, respectively, in conditioned me-
dium from 786-0-RC (RC; black bars) and 786-0-VHL (VHL; gray bars) cell lines. Detection of secreted protein by ELISA was performed in
at least three independent experiments.
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FN1 expression was not a¡ected by hypoxia in 786-0-VHL
cells or in 786-0-pRC cells, and suggested a HIF-independent
mechanism of regulation by VHL. To chemically mimic the
e¡ect of hypoxia we administered cobalt chloride to these cell
lines, thereby arti¢cially stabilizing HIF and stimulating HIF-
mediated transcription [28]. This method was able to repro-
duce hypoxia e¡ects on GLUT-1, VEGF, IGFBP3 and FN1
expression (data not shown).
Our data demonstrate positive regulation of FN1 by VHL
thereby suggesting the existence of a HIF-independent path-
way of transcriptional control by VHL. Our ¢ndings support
the hypothesis that VHL is positioned in both HIF-indepen-
dent and HIF-dependent pathways that are involved in ECM
deposition [14,29]. HIF-independent VHL transcriptional tar-
gets provide a possible link with the tumor suppressor mech-
anism of VHL. It is tempting to speculate that the induction
of genes in the presence of VHL and the downregulation of
these genes in the absence of VHL both play a role in the
development of the malignant properties of RCCs.
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oxia. C: Fibronectin mRNA expression does not respond to hypox-
ia in either the 786-0-RC or the 786-0-VHL cell lines.
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